MedTrace Logo

Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure

NCT00399269 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2009-06-11

No results posted yet for this study

Summary

To establish the efficacy and Safety of rHu-EPO-alpha in patients with anemia of Chronic Renal Failure.

Conditions

Interventions

DRUG

Recombinant Human Erythropoietin alpha

Sponsors & Collaborators

  • Cadila Pharnmaceuticals

    lead INDUSTRY

Principal Investigators

  • Dr. H. L. Trivedi, MD · IKDRC, Civil Hospital, Ahmedabad

  • Dr. Pankaj Shah, Nephrologist · IKDRC, Civil Hospital, Ahmedabad

  • Dr. Shishir Gang, Nephrologist · Muljibhai Patel Urological Hospital

  • Dr. Himanshu Patel, Nephrologist · Gujarat Kidney Foundation, Ahmedabad

  • Dr. Miten Mehta, Nephrologist · Anandabawa Kidney Dialysis Center, Jamnagar

  • Dr. Asit Mehta, Nephrologist · Apollo Hospitals, Ahmedabad

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Completion
2007-06-30

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00399269 on ClinicalTrials.gov